

Resource Summary Report

Generated by [dkNET](#) on Sep 15, 2026

RTCA Software

RRID:SCR_014821

Type: Tool

Proper Citation

RTCA Software (RRID:SCR_014821)

Resource Information

URL: <https://aceabio.com/product/rtca-dp/>

Proper Citation: RTCA Software (RRID:SCR_014821)

Description: Data acquisition and analysis software used for xCELLigence Real Time Cell Analysis SP, DP and MP instruments. The software is used to program and execute experiments and analyze data.

Synonyms: Real Time Cell Analysis (RTCA) Software, Real Time Cell Analysis Software, RTCA 2.0 Software

Resource Type: data acquisition software, data analysis software, data processing software, software application, software resource

Keywords: system management software, cell, analysis, real time, data acquisition, data analysis

Availability: Commercially available

Resource Name: RTCA Software

Resource ID: SCR_014821

Record Creation Time: 20220129T080322+0000

Record Last Update: 20260912T195822+0000

Ratings and Alerts

No rating or validation information has been found for RTCA Software.

No alerts have been found for RTCA Software.

Data and Source Information

Usage and Citation Metrics

We found 24 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

O'Reilly C, et al. (2026) LRRC15-CAR T Cells for the Treatment of Osteosarcoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 32(8), 1557.

Arnone AA, et al. (2025) Endocrine-targeting therapies shift the breast microbiome to reduce estrogen receptor-? breast cancer risk. Cell reports. Medicine, 6(1), 101880.

Min S, et al. (2025) Anticancer effect of a single-chain variable fragment against pro-matrix metalloproteinase-7 in colon cancer. Matrix biology : journal of the International Society for Matrix Biology, 135, 125.

Wang Q, et al. (2025) In vivo proteomic labeling reveals diverse proteomes for therapeutic targets. Molecular cell, 85(24), 4651.

Kinoshita S, et al. (2024) Rejuvenated iPSC-derived GD2-directed CART Cells Harbor Robust Cytotoxicity Against Small Cell Lung Cancer. Cancer research communications, 4(3), 723.

Nascentes Melo LM, et al. (2024) Selenoprotein O Promotes Melanoma Metastasis and Regulates Mitochondrial Complex II Activity. Cancer research.

Wolters RM, et al. (2024) Isolation of human antibodies against influenza B neuraminidase and mechanisms of protection at the airway interface. Immunity, 57(6), 1413.

Johnson NV, et al. (2024) Discovery and characterization of a pan-betacoronavirus S2-binding antibody. Structure (London, England : 1993), 32(11), 1893.

Shoji KF, et al. (2023) The mechanosensitive TRPV2 calcium channel promotes human melanoma invasiveness and metastatic potential. EMBO reports, 24(4), e55069.

Nakazawa K, et al. (2023) Piperacetazine Directly Binds to the PAX3::FOXO1 Fusion Protein and Inhibits Its Transcriptional Activity. Cancer research communications, 3(10), 2030.

Olivera I, et al. (2023) mRNAs encoding IL-12 and a decoy-resistant variant of IL-18 synergize to engineer T cells for efficacious intratumoral adoptive immunotherapy. Cell reports. Medicine, 4(3), 100978.

Batu Öztürk A, et al. (2023) Conditioned media of mouse macrophages modulates neuronal dynamics in mouse hippocampal cells. International immunopharmacology, 114, 109548.

Chen EC, et al. (2023) Systematic analysis of human antibody response to ebolavirus glycoprotein shows high prevalence of neutralizing public clonotypes. *Cell reports*, 42(4), 112370.

Sun R, et al. (2023) ROTACs leverage signaling-incompetent R-spondin for targeted protein degradation. *Cell chemical biology*, 30(7), 739.

Gilchuk P, et al. (2022) Standardized two-step testing of antibody activity in COVID-19 convalescent plasma. *iScience*, 25(1), 103602.

Berton S, et al. (2022) A selective PPM1A inhibitor activates autophagy to restrict the survival of *Mycobacterium tuberculosis*. *Cell chemical biology*, 29(7), 1126.

Suryadevara N, et al. (2021) Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein. *Cell*, 184(9), 2316.

Chen EC, et al. (2021) Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals. *Cell reports*, 36(8), 109604.

Greaney AJ, et al. (2021) Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition. *Cell host & microbe*, 29(1), 44.

Gilchuk P, et al. (2021) Pan-ebolavirus protective therapy by two multifunctional human antibodies. *Cell*, 184(22), 5593.